Pharmacokinetics and pharmacodynamics of the erythropoietin mimetibody™ construct CNTO 528 in healthy subjects

Clinical Pharmacokinetics

Volumn 48, Issue 9, 2009, Pages 601-613

  Pérez Ruixo, Juan José ^a,b   Krzyzanski, Wojciech ^c   Bouman Thio, Esther ^d   Miller, Bruce ^d   Jang, Haishan ^d   Bai, Stephen A ^d   Zhou, Honghui ^d   Yohrling, Jennifer ^d   Cohen, Adam ^e   Burggraaf, Jacobus ^e   Franson, Kari ^e   Davis, Hugh M ^d  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c UNIVERSITY AT BUFFALO   (United States)

^d CENTOCOR INC   (United States)

^e CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; CNTO 528; ERYTHROPOIETIN MIMETIC PEPTIDE 1 IMMUNOGLOBULIN G HEAVY CHAIN FUSION PROTEIN; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; COMPUTER MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG HALF LIFE; ERYTHROCYTE COUNT; ERYTHROPOIESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANEMIA; ANTIBODIES, MONOCLONAL; COMPUTER SIMULATION; DRUG DOSAGE CALCULATIONS; ERYTHROCYTE COUNT; ERYTHROPOIETIN; HALF-LIFE; HEMOGLOBINS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PEPTIDES, CYCLIC; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT FUSION PROTEINS; RETICULOCYTE COUNT; RETICULOCYTES; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 69849106825     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11317190-000000000-00000     Document Type: Article

References (36)

1. Koury MJ, Sawyer ST, Brandt SJ. New insights into erythropoiesis. Curr Opinion Hematol 2002; 9: 93-100
2. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med 2003; 228: 1-14
3. Henry DH, Bowers P, Romano MT, et al. Epoetin alfa: clinical evolution of a pleiotropic cytokine. Arch Inter Med 2004; 164: 262-76
4. Wrighton NC, Farrell FX, Chang R, et al. Small peptidesas potent mimetics of the protein hormone erythropoietin. Science 1996; 26: 273: 458-64
5. Haber E. Engineered antibodies as pharmacological tools. Immunol Rev 1992; 130: 189-212
6. Heavner GA, Knight DM, Ghrayeb J, et al., inventors. Mammalian CH1 deleted mimetibodies, compositions, methods and uses. World Intellectual Property Organization WO 2004/00242, 2004
7. Bugelski P, Nesspor T, Spinka-Doms T, et al. Pharmacokinetics and pharma-codynamics of CNTO 528, a novel erythropoietin receptor agonist in normal and anemic rats. Blood 2005; 106: 4261
8. Bouman-Thio E, Franson K, Miller B, et al. A phase 1 single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmaco-dynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. J Clin Pharmacol 2008; 48: 1197-207
9. Hayashi N, Zuideveld KP, Jordan P, et al. A mechanism-based PK/PD model predicts the time course of hematological responses for epoetin beta [abstract no. 396]. Twelfth Annual Meeting, Population Approach Group in Europe; 2003 Jun 12-13; Verona [online]. Available from URL: http://www. page-meeting. org/?abstract=396 [Accessed 2009 Jul 1]
10. Ramakrishnan R, Cheung WK, Wacholtz MC, et al. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol 2004; 44: 991-1002
11. Krzyzanski W, Jusko WJ, Wacholtz MC, et al. Pharmacokinetic and phar-macodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci 2005; 26: 295-306
12. Zhang L, Beal SL, Sheiner LB. Simultaneous vs sequential analysis for popu-lation PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn 2003; 30: 387-404 (Pubitemid 38221931)
13. Krzyzanski W, Ramakrishnan R, Jusko WJ. Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm 1999; 27: 467-89
14. Perez-Ruixo JJ, Kimko HC, Chow AT, et al. Population cell life span models for effects of drugs following indirect mechanisms of action. J Pharmacokinet Pharmacodyn 2005; 32: 767-93
15. Loeffler M, Pantel K, Wulff H, et al. A mathematical model of erythropoiesis in mice and rats. Part 1: Structure of the model. Cell Tissue Kinet 1989; 22: 13-30 (Pubitemid 19241657)
16. Gaddum JH. Series of drug antagonism. Pharmacol Rev 1957; 9: 211-8
17. Papayannopoulou T, Abkowitz J. Biology of erythropoiesis, erythroid differentiation and maturation. In: Hoffman R, Benz EJ, Shattil SJ, et al., editors. Hematology: basic principles and practice. New York: Churchill Livingstone, 1995
18. Efron B, Tibshirani R. An introduction to the bootstrap. London: Chapman and Hall, 1993
19. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001; 28: 171-92
20. Olsson-Gisleskog P, Jacqmin P, Perez-Ruixo JJ. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects. Clin Pharmacokinetic 2007; 46: 159-73
21. Agoram B, Sutjandra L, Sullivan JT. Population pharmacokinetics of darbe-poetin alfa in healthy subjects. Br J Clin Pharmacol 2006; 63: 41-52
22. Krzyzanski W, Perez-Ruixo JJ. An assessment of recombinant human erythro-poietin effect on reticulocyte production rate and lifespan distribution in healthy subjects. Pharm Res 2007; 24: 758-72
23. Macdougall IC, Roberts DE, Coles GA, et al. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 1991; 20: 90-113
24. de Francisco ALM, Sulowicz W, Klinger M, et al., on behalf of the BA16260 Study Investigators. Continuous Erythropoietin Receptor Activator (C. E. R. A. ) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract 2006; 60: 1687-96
25. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28: 507-32
26. Chapel S, Veng-Pedersen P, Hohl RJ, et al. Changes in erythropoietin pharma-cokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 2001; 298: 820-4
27. Woo S, Krzyzanski W, Jusko WJ. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn 2007; 34: 849-68
28. Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992; 51: 76-89
29. Chapel SH, Veng-Pedersen P, SchmidtL, etal. Apharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep. J Pharmacol Exp Ther 2000; 295: 346-51
30. Veng-Pedersen P, Gillespie WR. A system approach to pharmacodynamics I: theoretical framework. J Pharm Sci 1988; 77: 39-47
31. Sharma A, Ebling WF, Jusko WJ. Precursor-dependent indirect pharmaco-dynamic response model for tolerance and rebound phenomena. J Pharm Sci 1998; 87: 1577-84
32. McKenzie SB. Textbook of hematology. Baltimore (MD): Williams & Wilkins, 1996
33. Koury MJ, Bondurant MC. The molecular mechanism of erythropoietin action. Eur J Biochem 1992; 210: 649-63
34. Alfrey CP, Rice L, Udden MM, et al. Neocytolysis: physiological down-regulator of red-cell mass. Lancet 1997; 349: 1389-90
35. Imagawa S, Yamamoto M, Miura Y. Negative regulation of the erythro-poietin gene expression by the GATA transcription factors. Blood 1997; 89: 1430-9
36. 0 flanking region. Gene 1993; 128: 227-36